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The search for non-invasive or minimally invasive approaches for the 
treatment of cancer has led to the development of different therapeutic 
regimes and one such regime is photodynamic therapy (PDT). PDT is a 
non-thermal treatment based on the synergy of three elements: the ad-
ministration of a photosensitizer drug; light at a precise wavelength; and 
the presence of oxygen. When these three components are combined, 
they lead to the formation of reactive oxygen species (ROS), resulting in 
a complex cascade of events and subsequent cell death Studies revealed 
that PDT can prolong survival in patients with inoperable cancers and 
significantly improve the quality of life. With a number of recent techno-
logical improvements, PDT has the potential to become integrated into 
the mainstream strategy for cancer treatment. In this review, we have 
addressed the most important biological and physicochemical aspects of 
PDT, summarized its clinical status and provided an outlook for its poten-
tial future development. We also discussed the factors that hamper the ex-
ploration of this effective therapy and what should be changed to render it 
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1. Introducation
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body [1,2]. Not all tumors are 
cancerous; benign tumors do not spread to other parts 
of the body [2]. Possible signs and symptoms include a 
lump, abnormal bleeding, prolonged cough, unexplained 
weight loss and a change in bowel movements [3]. While 
these symptoms may indicate cancer, they may have oth-
er causes [3]. Cancer can be detected by certain signs and 
symptoms or screening tests [1]. It is then typically further 
investigated by medical imaging and confirmed by biopsy 
[4]. Cancer has been one of the major threats to the lives 
of human beings for centuries [5]. Current cancer therapies 
mainly include surgery, chemotherapies, radiotherapies, 
hormonal therapy, targeted therapy and palliative care. 
Which treatments are used depends on the type, location 
and grade of the cancer as well as the patient's health and 
preferences. The treatment intent may or may not be cura-
tive. While surgery in many occasions is not able to com-
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pletely remove all cancer cells in the human body, chemo-
therapy and radiotherapy all suffer from their severe toxic 
side effects to normal tissues and limited specificities to 
cancer cells [6]. Despite progress in basic research that has 
given us a better understanding of tumor biology and led 
to the design of new generations of targeted drugs, recent 
large clinical trials for cancer, with some notable excep-
tions, have been able to detect only small differences in 
treatment outcomes [7,8]. Moreover, the number of new 
clinically approved drugs is disappointingly low [9]. These 
sobering facts indicate that to make further progress, it is 
necessary to put an emphasis on other existing but still un-
derappreciated therapeutic approaches. Research has been 
focused on developing alternate treatment modalities that 
are safe, potent, and cost-effective. Photodynamic therapy 
(PDT) is an alternative tumor-ablative and function-spar-
ing oncologic intervention. Since its inception in early 
1900s and its first modern demonstration by Dougherty et 
al. in 1975 [10], PDT has undergone extensive investiga-
tions and has emerged as a disease site specific treatment 
modality. Photodynamic therapy (PDT) has the potential 
to meet many currently unmet medical needs. Although 
still emerging, it is already a successful and clinically 
approved therapeutic modality used for the management 
of neoplastic and non-malignant diseases. PDT was the 
first drug-device combination approved by the US Food 
and Drug Administration (FDA) almost 2 decades ago, 
but even so remains underutilized clinically. PDT is a la-
ser treatment that requires the selective incorporation of 
a drug, i.e., a photosensitizer (PS), into the targeted cells/
tissues, followed by the subsequent exposure of the target 
region to light of appropriate wavelengths, visible/near 
infrared (NIR) light, to produce reactive oxygen species 
(ROS) such as singlet oxygen (1O2) for sequential cancer 
eradication, leading to cellular death, vascular shutdown, 
and immune activation [11].  Hence, PDT employs 3 non-
toxic components that by its own do not have any toxic 
effects on the biological systems, unlike chemotherapy 
drugs that induce systemic toxicity and ionizing light 
of radiation therapy that damages neighbouring normal 
tissues. Clearly, PDT has its own merits compared to the 
conventional treatment methods due to its minimal inva-
siveness, repeatability without cumulative toxicity, excel-
lent functional and cosmetic results, reduced long-term 
morbidity and improved quality of life of the patients [12]. 
Since its regulatory approval as a cancer therapy, PDT has 
been subject of numerous studies and has proven to be an 
effective form of cancer therapy. This article would com-
prehensively review the recent advances regarding the de-
velopment of PDT for cancer treatment. Herein a variety 
of inorganic and organic NIR-absorbing compounds ex-
plored for PDT cancer treatment have been summarized. 
The combination of PDT with other therapeutic approach-
es such as chemotherapy has also been discussed. Finally, 
examples from the most recent studies has been given to 
show in which directions PDT is headed, both in the near 
and distant future. The future prospects and challenges in 
this rapidly growing field have also been addressed. The 
aim of this review is therefore to analyze the current state 
of PDT and to give insights as to how the future of PDT 
will look like as a (first-line) treatment for cancer.
2. Principles of Photodynamic Therapy
PDT consists of 3 essential components: photosensitizer 
(PS), light and oxygen [13]. None of these is individually 
toxic, but together they initiate a photochemical reaction 
that culminates in the generation of a highly reactive 
product termed singlet oxygen (1O2). The latter can rapid-
ly cause significant toxicity leading to cell death via apop-
tosis or necrosis [13]. A photosensitizer (PS) is administered 
systemically or topically. After a period of systemic PS 
distribution, it selectively accumulates in the tumor. Irra-
diation activates the PS and in the presence of molecular 
oxygen triggers a photochemical reaction that culminates 
in the production of singlet oxygen (1O2). 
Figure 1. The Principles of Photodynamic Therapy (PDT) 
[14]
Irreparable damage to cellular macromolecules leads to 
tumor cell death via an apoptotic, necrotic or autophagic 
mechanism, accompanied by induction of an acute local in-
flammatory reaction that participates in the removal of dead 
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cells, restoration of normal tissue homeostasis and some-
times, in the development of systemic immunity (Figure 1). 
3. Photodynamic Therapy for Treatment of 
Different Kinds of Cancers
PDT has been used clinically in the treatment of human 
carcinomas since it was introduced by Dougherty et al. in 
1978 [15], and the clinical significance of PDT in the treat-
ment of digestive tract carcinomas, such as in the oesoph-
agus, stomach, and bile duct, were reported in a Japanese 
series [16]. The first clinically approved photosensitizer was 
a hemato-porphyrin derivative, such as porfimer sodium. 
Moreover, many clinical trials are currently under way to 
study the potential of PDT in the treatment of various oth-
er types of cancers [17].
3.1 Photodynamic Therapy of Breast Cancer
Breast cancer is the most frequently diagnosed and one of 
the leading causes of death among women worldwide [18]. 
Although breast cancer mortality is falling, particularly 
in developed countries, its incidence is raising [19-21].With 
the advent of breast screening more cancers are being 
diagnosed early and therefore often require less extensive 
surgical treatment when combined with adjuvant thera-
pies. The use of novel technologies to treat all stages of 
breast cancer is desirable because they allow more options 
to be available for all patients, including those who are 
not eligible for standard management. However, in order 
to be successful they need to offer additional benefits 
or fewer side-effects when compared to the standard of 
care. Here, photodynamic therapy (PDT) is reviewed with 
regard to the components that make it a successful. The 
first clinical application for this technology in breast can-
cer treatment was in the treatment of skin metastases in 
chest wall recurrence [22,23]. The initial series of 37 patients 
with breast carcinoma chest wall recurrence treated with 
PDT by Khan et al., in 1993 [24] and that was an effective 
treatment in selected patients, although there was some 
variation in the extent of the response. Photofrin was used 
as the photosensitizer in this light-dose-escalation study 
to determine the minimal light dose at which an effective 
response could be achieved. The results showed that five 
patients achieved a complete response, 13 demonstrated 
partial responses, and 19 showed no benefit [24]. The extent 
and type of the recurrent disease were strong determinants 
of the likelihood of response. Minimal and nodular dis-
ease responded well to PDT; partial responses were seen 
in patients with disease of moderate extent. 
Polymeric micelles composed of vitamin E derivatives 
arise as promising candidates for the treatment of breast can-
cer [25]. Among them, D-α-tocopheryl succinate (TOS) and 
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) 
may be used to prepare micelles for cancer therapy and these 
are already approved by Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) as pharma-
ceutical solubilizers [26,27]. Pais-Silva et al. produced and char-
acterized IR780-loaded TPGS-TOS micelles (IR780-TTM) 
to evaluate their application in breast cancer phototherapy. 
IR780 was chosen due to its versatility as a light-responsive 
compound and TPGS and TOS due to their ability to form 
micelles and to their intrinsic anticancer activity. Their re-
sults demonstrated that IR780-loaded micelles with suitable 
properties were obtained by using specific TPGS and TOS 
weight feed ratios during micelles formulation [28]. Via assays 
demonstrated that the IR780-loaded micelles induce a cyto-
toxic effect on cancer cells upon exposure to NIR irradiation 
through the generation of ROS (PDT). This effective abla-
tion of cancer cells was achieved by using the lowest IR780 
concentration reported until now and it was suggested that 
TPGS and TOS might have an important role in such effect 
through their intrinsic capacity to generate ROS. Moreover 
the capability of the IR780-loaded micelles to act as PTT 
and imaging agents, was also demonstrated which widens 
their therapeutic and diagnostic potential. Wyss et al. treated 
breast cancer chest wall recurrence in seven patients with 
complete response [29]. In this short series the photosensitizer 
meta-tetra (hydroxyphenyl) chlorin (m-THPC) was injected 
intravenously. Response to treatment did not differ with use 
of the two different drug dose protocols. Healing time de-
pended mainly on the size of the illumination field but not on 
the light dose. Similarly Cuenca et al. found that PDT was an 
effective treatment for the palliation of chest wall recurrence 
using Photofrin [30]; 500 separate cutaneous truncal lesions 
were treated in 14 patients [30]. The follow-up period ranged 
from 6 to 24 months. While all patients demonstrated tumor 
necrosis, and 9 out of 14 had complete responses and several 
had regression of untreated lesions, there was no effect on 
disease progression. Li et al., in 2011 combined PDT with 
immune therapy in a trial assessing safety and efficacy of 
laser immunotherapy (LIT) for the treatment of metastatic 
breast cancer [31]. All 10 patients who were enrolled had either 
stage 3 or 4 diseases, and 8 patients were suitable for final 
evaluation [31]. Only 1 patient had complete response; 4 pa-
tients had partial responses, 2 maintained stable disease, and 
2 patients had disease progression [31]. There was transient 
thermal injury, the prolonged duration of which was strongly 
associated with previous radiotherapy. However, there were 
no serious adverse effects or deaths due to this treatment. 
While the application of immunotherapy to treat cancers is 
not new, this study demonstrated that adjuvant treatment 
with immunotherapy following PDT may improve its effec-
DOI: https://doi.org/10.30564/jim.v8i1.780
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tiveness and represents a viable future treatment of tumors at 
distant sites.
Further clinical research may perhaps lead to PDT 
being considered as a method of vaccination against tu-
mors [32]. This clearly would be of great advantage as PDT 
treatment in patients treated for primary breast cancer 
could also result in acquired immunity against the cancer 
at distant sites for all metastases of the same tumor clone. 
Under these circumstances, PDT's current position as a 
potential complementary adjuvant therapy could be ex-
tended to become a standard of care in breast cancer treat-
ment. Further research is required if PDT is to be used 
successfully in primary breast cancer.  
3.2 Photodynamic Therapy in Colorectal Cancer 
Treatment
Colorectal cancer (CRC) is the third most common cancer 
in men (10.0% of the total incidences) and the second in 
women (9.2%, respectively) worldwide. About 750,000 
deaths from CRC are predicted in 2015 globally, account-
ing for 8.5% of all cancer deaths predicted in this year, 
which makes CRC the fourth most common cause of 
death from cancer [33-35]. According to the data from 2011, 
approximately 20-25% of patients with CRC already have 
metastases at the time of diagnosis and 50-60% of the 
remainder will develop metastases [36]. The treatment op-
tions and prognosis for patients with CRC have improved 
through the development of novel drugs and treatment 
regimens [37]. However, the increasing resistance of tumor 
cells toward chemotherapeutic and biologic drugs used in 
CRC [38] as well as non-specific toxicity of these drugs on 
healthy tissues [39] creates a necessity to find other methods 
of CRC therapy. One of these methods is photodynamic 
therapy (PDT) [40] involving interaction between light, pho-
tosensitizer and oxygen to destruct tumor tissue through 
direct oxidative damage, vascular shutdown and activation 
of immune response against cancer cells [41,42]. The advan-
tages of PDT over conventional chemotherapy are: higher 
tumor selectivity, lack of cross-resistance which enables 
the use of PDT in cases of recurrent tumors, wide range 
of total light and drug dose, allowing multiple application 
of PDT toward the same tumor as well as very good cos-
metic effect with small or no scarring [43]. The majority of 
preclinical studies concerning possibility of PDT applica-
tion in colon and rectal cancer are focused on phototoxic 
action of photosensitizers towards cultured colorectal tu-
mor cells via. The via research simplifies the system under 
study comparing to living organism so that investigator 
can focus on the limited number of cell components and 
interactions between them [44].
3.3 Digestive Tract Carcinomas
PDT has been approved as a curative treatment in the di-
gestive tract for super-ficial carcinoma of the oesophagus 
and stomach under the national health insurance system 
by Japan’s Ministry of Health and Welfare since 1994. 
Oesophageal cancer accounted for 3.2% of the newly 
diagnosed cancers in 2012. With a very poor mortality to 
incidence ratio, it is the sixth most common cause of can-
cer related death (4.9% of total) [45]. Oesophageal cancer 
histology differs by location: oesophageal squamous cell 
carcinoma (ESCC) is located in the upper and middle part 
of the oesophagus while adenocarcinoma (ADC) is mostly 
located in the lower part. Locally advanced oesophageal 
cancer can be surgically removed by esophagectomy in 
operable patients but postoperative morbidity and mor-
tality occur regularly and long-term outcome is poor [46]. 
Only small advantages of neoadjuvant CT and CRT to 
improve treatment outcome have been observed [46,47]. 
Peri-operative chemo-therapy (PCT) or chemo-radiation 
therapy (CRT) appears beneficial but the advantage was 
more pronounced for younger patients as no survival ad-
vantage was seen for the elderly patients [48]. CRT is used 
as definitive treatment option for ESCC but residual or 
recurrent lesions remain a major obstacle showing need of 
improved therapies. Moreover, reducing morbidity associ-
ated with CT would also improve current treatment strate-
gies, which is why PDT has great potential. Clinical stud-
ies showed the curative potential of Photofrin®-PDT for 
BE and early esophageal cancer. In a retrospective study, 
Photofrin®-PDT applied with curative intend proved 
successful in Barretts esophagus (BE) patients with 
high grade dysplasia (HGD), an indication with a higher 
chance of progression to cancer. It was less effective in 
patients who had ADC or ESCC, especially with larger le-
sions [49]. A similar study supports this data by stating PDT 
proved effective in treating smaller BE or ADC lesions 
but complete ablation was less likely with lesions over 
3 cm in length [50]. May be even more important than BE 
length is oesophageal wall thickness, as thicker walls have 
a lower chance of achieving successful results with Pho-
tofrin®-PDT [51]. Photofrin®-PDT is indeed effective but 
it appears that taking lesion length, thickness and possibly 
several genetic biomarker levels into account when estab-
lishing PDT dosage, can still improve Photofrin®-PDT ef-
ficacy. It is considered an effective component of adjuvant 
therapy for patients with dysphagia that are unfit for, or 
refuse, surgery. As part of a multimodal approach, Photof-
rin®-PDT has shown good results with improving the pa-
tients’ quality of life by effectively and immediately palli-
ating dysphagia [52]. A randomised controlled, dose-finding 
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study showed comparable or even better efficacy using 
5-ALA compared to Photofrin® in patients with high 
grade dysplasia (HGD). Moreover, PDT using 5-ALA was 
carried out without the complications seen with Photof-
rin® due to improved localisation [53]. Studies with second 
generation PSs show better efficacy and lower morbidity 
but additional trials are needed to potentially implement 
them as first-line treatment of oesophageal cancer.
Photofrin-PDT is clinically applied for unresectable bile 
duct carcinomas worldwide; however, PDT for unresect-
able bile duct carcinoma was used in clinical research trials 
at a small number of institutes, but was not approved by the 
national health insurance system in Japan. Between 1998 
and 2006, cancer institutes in Europe showed improved 
patient status and survival benefits of photofrin-PDT for 
unresectable bile duct carcinomas in randomized or phase 
II prospective trials [54,55]. Thus, PDT has become a promis-
ing modality for local treatment of bile duct carcinoma and 
PDT using the new photosensitizer, temoporfin, recently 
showed a decrease of phototoxicity and treatment efficacy 
[56]. Thus, PDT has been found to be potentially safe and 
effective treatment for digestive tract carcinomas, which 
lead to increased quality of life, prolonged tumor progres-
sion-free period and related increased overall survival ac-
companied by other therapy modalities.
3.4 Head and Neck Tumors
PDT has been successfully employed to treat early carci-
nomas of the oral cavity, pharynx, and larynx, preserving 
normal tissue and vital functions of speech and swallow-
ing [57]. Biel reported the largest series of over 300 patients 
accrued over a 15- year clinical time period and treated 
with porfimer sodium-mediated PDT [58]. The treated le-
sions, there were predominantly squamous cell carcinoma 
(SCCs) of the oral cavity, pharynx, or larynx, Kaposi sar-
coma, melanoma, and SCC in the head and neck area [59]. 
Among the reported group, 133 patients presented with 
recurrent or primary CIS, T1N0 and T2N0 laryngeal car-
cinomas and were treated with PDT with curative intent. 
After a single PDT procedure, the patients were followed 
on average for 96 months and at 5 years demonstrated a 
90% cure rate. The second group of patients who under-
went PDT consisted of 138 patients with CIS and T1N0 
SCCs of the oral cavity. Similarly, one PDT treatment was 
delivered and the patients were followed for up to 211 
months. All patients were reported to achieve complete 
pathological and clinical responses and the cure rate at 
5 years remained at 100%. PDT was also used for pa-
tients with more advanced stages of oral cavity lesions. 
Fifty-two patients with T2N0 as well as T3N0 SCC also 
received a single PDT treatment that led to complete 
pathological and clinical response, affording a 100% cure 
rate at 3 years. Overall, over 500 patients with early stage 
oral cavity, larynx, pharynx, and nasopharynx lesions 
were treated with porfimer sodium-based PDT worldwide 
with similar success [60-62]. The intense development of a 
second generation of PSs has led to their entering clinical 
application in head and neck lesions as well [63]. Several 
series have reported on the use of the second-generation 
PSs such as ALA and temoporfin [64,65]. The study by Hop-
per et al. [64] of patients with early oral cancer, in whom 
the tumors measured up to 2.5 cm in diameter, reported a 
complete response rate of 85% (97 of 114 patients) at 12 
weeks and a disease-free survival rate of 75% at 2 years. 
In another study by Copper et al, [66] PDT was used in the 
treatment of a total of 27 patients with 42 second or mul-
tiple primary head and neck tumors. Perhaps the most in-
teresting study reported the application of temoporfin-me-
diated PDT for advanced disease. A total of 128 patients 
with advanced head and neck cancer were treated with a 
single PDT session. [67] The patients included in this study 
had failed conventional therapy or were unsuitable for 
such treatment. PDT delivered 96 hours after temoporfin 
administration allowed for 100% tumor mass reduction in 
43% of lesions and the remaining lesions were reduced by 
at least 50%. In this trial, tumor mass reduction was mea-
sured for each lesion by multiplying the lesion’s length 
by its width. The 100% tumor mass reduction represented 
a complete local tumor clearance. A relatively limited 
study that has been conducted with ALA for head and 
neck lesions reported results that were slightly inferior 
to those observed with porfimer sodium and temoporfin 
[68,69]. Taken together, the data from phase 1/2 trials strong-
ly suggested that PDT could be an effective primary and 
alternative treatment modality for patients presenting with 
early head and neck tumors and that further research in 
this area, including randomized trials, is needed. 
3.5 Urinary System Tumors
3.5.1 Prostate Cancer
Patients with prostate cancer who elect to undergo defini-
tive radiotherapy have limited options for salvage therapy 
for isolated local failure. Unlike chemotherapy or radio-
therapy, the mechanism of cell killing by PDT is not de-
pendent on DNA damage or cell cycle effects, decreasing 
the chances of therapy cross-resistance and eliminating 
late normal tissue effects such as second malignancy. All 
of these factors combine to make prostate cancer an attrac-
tive target for clinical trial development. Several groups 
have published clinical trial results for prostate PDT using 
second-generation PSs. In a pilot study of temoporfin-me-
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diated PDT, 14 patients who experienced biopsy con-
firmed local failure after definitive radiotherapy for early 
stage prostate cancer were treated using up to 8 implanted, 
interstitial, cylindrically diffusing optical fibers [70]. Anoth-
er group has studied motexafin lutetium (MLu) as a PS for 
PDT of the prostate [71,72]. In the phase 1 trial, 17 patients 
with biopsy confirmed, locally recurrent prostate cancer 
after definitive radiotherapy were treated with increasing 
doses of 732 nm (red) light using interstitial fibers. The 
primary goal of this trial was to determine the maximally 
tolerated dose and dose-limiting toxicities of MLu-medi-
ated prostate PDT, and one important secondary goal was 
to begin to develop the capability to perform real-time 
measurements of tissue optical properties, tissue levels of 
oxygen, and PS to eventually allow real-time light fluence 
modulation that would provide a more homogenous dose 
of PDT to the entire prostate gland. As in the temoporfin 
study, one patient developed a urorectal fistula that was at-
tributed to inhomogeneity of the light dose. The remainder 
of toxicities observed in these patients were mild to mod-
erate and consisted of urinary toxicities, including stress 
incontinence. Although not designed to measure efficacy, 
a significant difference was found in time to biochemical 
failure (prostate-specific antigen recurrence between the 
low and high PDT dose cohorts, providing some evidence 
of biochemical and pathologic disease response to PDT. 
Another group has investigated vascular targeted PDT 
using palladium (Pd)-bacteriopheophorbide (padoporfin)–
mediated PDT and a short drug-light interval [73]. In the 
phase 1 trial, 24 patients with biopsy confirmed local 
failure after definitive radiotherapy for prostate adeno-
carcinoma were treated with padoporfin-mediated PDT 
using 2 interstitial fibers. [74] This study demonstrated that 
vascular-targeted PDT could be safely performed in this 
patient population. In the follow-up phase 2 study, 28 pa-
tients were treated with increasing light doses [75]. After 6 
months of follow-up, less residual cancer was noted on bi-
opsy as the light dose increased. All had negative biopsies 
at follow-up if greater than 60% of the prostate was deter-
mined to be avascular by post-PDT magnetic resonance 
imaging (MRI). Toxicities were significant, with 2 patients 
developing urethrorectal fistulas. This study demonstrat-
ed the potential for pathologic complete response over a 
short-term follow-up. Together, these studies suggested 
that although PDT to the prostate is feasible, comprehen-
sive treatment of the entire gland will be necessary and 
improved techniques and dosimetry will be critical in pro-
viding an acceptable toxicity profile. 
3.5.2 Bladder Cancer
Bladder cancers, which are often superficial and multi-
focal, can be assessed and debulked endoscopically. In 
addition, the geometry of the bladder should allow for 
improved and homogeneous delivery of light. These fac-
tors make superficial bladder cancer an attractive target 
for PDT. In one study, focal HPD-mediated PDT was used 
to treat 50 superficial bladder transitional cell carcinomas 
(TCCs) in 37 patients and achieved a 74% complete re-
sponse rate [76]. Another study used HPD-mediated PDT 
to treat the entire bladder wall for 34 patients with refrac-
tory CIS of the bladder and achieved a 73.5% complete 
response rate at 3 months [77]. However, by 2 years, 77.8% 
of these patients experienced disease recurrence. In these 
studies, treatment of superficial bladder cancer with PDT 
is generally well tolerated, with dysuria, hematuria and 
skin photosensitivity being the most common acute tox-
icities. However, bladder wall fibrosis/ diminished blad-
der capacity has been and continues to be a problem in 
some treated patients. With improved dosimetry and the 
use of porfimer sodium as a PS, other investigators have 
achieved durable complete response rates as high as 60% 
for patients with refractory bladder CIS or superficial TCC 
[78,79]. Studies of locally applied (intravesical) ALA demon-
strate that similar durable complete response rates of 52% 
to 60% at 2 to 3 years can be achieved for patients with 
treatment-refractory bladder CIS without the prolonged 
skin photosensitivity experienced when using systemic 
porfimer sodium [80,81].
Although most of the patients treated with bladder 
PDT are refractory to BCG, one randomized controlled 
study has compared a single porfimer sodium-mediated 
PDT with multiple BCG treatments (induction plus main-
tenance) and found that these therapies are equivalent in 
durable treatment response [82]. Studies combining intra-
vesical immunotherapies such as BCG or chemotherapies 
such as mitomycin C with PDT showed that these thera-
pies might significantly enhance the PDT responsiveness 
of bladder tumors [83,84]. Despite these promising results, 
PDT for bladder cancer remains largely investigational 
with limited use. PDT for bladder cancer is approved 
in Canada and in some EU nations but has not been ap-
proved by the US FDA.
3.6 Non-Small Cell Lung Cancer and Mesothelioma 
PDT for non-small cell lung cancer (NSCLC) was first 
used in 1982 by Hayata et al. to achieve tumor necrosis 
and reopening of the airway [85]. PDT for lung cancer is 
particularly useful for (1) patients with advanced disease 
in whom PDT is used as a palliation strategy [86] and (2) 
patients with early central lung cancer when patients are 
unable to undergo surgery [87]. PDT is considered to be 
more specific and lesion-oriented compared with other 
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available modalities and produces less collateral damage, 
and therefore fewer complications. Indeed, a randomized 
trial of PDT versus Nd:YAG laser therapy for obstructing 
NSCLC lesions showed equal initial efficacy for these 2 
treatments, with a longer duration of response noted for 
PDT [88]. PDT plus palliative radiation also appears to in-
crease the time to bronchus reocclusion when combined 
compared with radiation alone [89]. In patients with early 
stage lung cancer, PDT has been used to successfully treat 
patients for whom surgery is not feasible. In one phase 2 
study, 54 patients with 64 lung carcinoma lesions under-
went porfimer sodium-mediated PDT and showed an 85% 
complete response rate with a 6.5% local failure rate at 
20.2 months [90]. Other studies have supported these excel-
lent results, with complete response rates averaging 73% 
in studies totaling 359 patients [91]. Recently, Usuda et al [92] 
reported a series of 70 cancer lesions measuring 1.0 cm or 
less in diameter and 21 lesions measuring greater than 1.0 
cm in diameter treated with PDT with talaporfin. The com-
plete response rates were 94.3% (66 of 70 patients) and 
90.4% (19 of 21 patients), respectively. PDT with talapor-
fin was capable of destroying the residual cancer lesions 
observed after the mass of large tumors had been reduced 
by electrocautery. Another report [93] described the results 
of 529 PDT procedures performed on 133 patients who 
presented with NSCLC (89 patients), metastatic airway 
lesions (31 patients), small cell lung cancer (4 patients), 
benign tumors (7 patients), and other (unspecified) lung 
conditions (2 patients). The lesions were most common-
ly located in the main stem bronchi (71 patients). Most 
patients received 2 treatments during a 3-day hospitaliza-
tion and returned in 2 weeks for 2 additional PDTs. The 
authors concluded that PDT can be safely and effectively 
used in the described setting, leading to improved dys-
pnea in selected patients. Malignant pleural mesothelioma 
(MPM) is a cancer of the pleura that, similar to NSCLC 
with pleural spread, has no currently available curative 
options. In a phase 2 study of porfimer sodium mediated 
PDT after extrapleural pneumonectomy for MPM, patients 
with stage I and II disease experienced a median survival 
of 36 months with a 2-year survival rate of 61%, whereas 
patients with stage III and IV disease experienced a medi-
an survival time of 10 months [94]. Both of these rates were 
significantly improved compared with historical series of 
surgery alone. One important finding in these studies of 
resection with PDT for MPM is that a lung-sparing, tumor 
debulking surgery can be combined with PDT to achieve 
local control rates similar to those observed with ex-
trapleural pneumonectomy. Indeed, a more recent study of 
macroscopically complete, lung-sparing surgical debulk-
ing followed by intraoperative porfimer sodium-mediated 
PDT for patients with locally advanced MPM found a 
median survival that had not been reached with a 2.1-year 
median follow-up in patients after radical pleurectomy 
with PDT [95]. Thus, PDT for MPM needs to be further 
evaluated in clinical trials of lung-sparing surgery. 
3.7 Brain Tumors
PDT is currently undergoing intensive clinical investi-
gation as an adjunctive treatment for brain tumors [96].
The major tumor lesions particularly suitable for PDT 
treatment are newly diagnosed and recurrent brain tumors 
due to their high uptake of PSs. Since the early 1980s, 
close to 1000 patients worldwide have received PDT for 
brain lesions. Perria et al. [97] reported one of the earliest 
attempts to use PDT to treat the postresection glioma 
cavity in humans, and Kaye et al [98] reported a phase 1/2 
trial involving 23 patients with glioblastoma multiforme 
(GBM) and anaplastic astrocytoma (AA). Other brain le-
sions treated with PDT included malignant ependymomas, 
[99,100] malignant meningiomas, [101] melanoma and lung 
cancer brain metastasis, [98,101] and recurrent pituitary ade-
nomas [102]. The initial trials provided encouraging results, 
and the authors concluded that PDT can be used as an 
adjuvant therapy in patients with brain tumors. The PSs 
used to date were various formulations of HPDs (porfimer 
sodium) and ALA as well as temoporfin. The light sourc-
es used to activate those PSs included lamps, dye lasers, 
gold vapor potassium titanyl phosphate dye lasers, and 
diode lasers. Currently, PSs are being evaluated both as 
intraoperative diagnostic tools by means of photodetection 
(PD) and fluorescence-guided resection (FGR) as well as 
during PDT as an adjunctive therapeutic modality [101,103-
105]. All 3 approaches take advantage of the higher uptake 
of PS by the malignant cells and are used intraoperatively. 
The most recently published trials that employed PD, 
FGR, and PDT provided additional encouraging results, 
but the initial delay in tumor progression did not translate 
to extended overall survival [106]. Muller and Wilson re-
ported the results of a prospective randomized controlled 
trial using adjuvant porfimer sodium-mediated PDT in the 
study group [107].The 96 patients treated for supratentorial 
gliomas with PDT with porfimer sodium at St. Michael’s 
Hospital in Toronto, Ontario, Canada were randomized to 
2 groups that received either 40 J/cm2 or 120 J/cm2. The 
patients who received the higher dose (48 patients) sur-
vived on average for 10 months, whereas the 49 patients 
in the low-dose group survived on average 9 months; the 
difference between both groups was not statistically sig-
nificant (P ¼ .05). Stummer et al. reported the results of 
the ALA study group, a multicenter prospective random-
ized controlled trial in Germany [108]. This trial compared 
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the effectiveness of ALA-based FGR with conventional 
surgery. The 322 patients with suspected malignant gli-
omas were followed for 35.4 months. Patients random-
ized to the FGR group demonstrated much better time 
to progression (5.1 months) compared with the controls 
(3.6 months), which translated into a greater survival of 
16.7 months versus 11.8 months, respectively. Howev-
er, the difference in overall survival was not statistically 
significant. The current standard therapies that include 
surgery, radiotherapy, and chemotherapy afford a median 
survival of approximately 15 months and although there 
are limited data comparing PD, FGR, and photodiagno-
sis with those standard therapies, the initial results from 
randomized trials are encouraging. It remains to be seen 
whether PDT for brain tumors remains a palliative or, at 
most, an alternative treatment modality. The new classes 
of PSs, the better understanding of dosimetry, and further 
improvement in technology may significantly change the 
currently achieved clinical outcome. In addition, preclin-
ical data indicating that protracted light delivery may in-
crease the therapeutic index of PDT in the brain combined 
with newer technologies such as implantable LED-based 
light delivery systems could lead to significant improve-
ments in treatment outcomes [96]. 
4. X-Ray-Induced Photodynamic Therapy
Achieving effective treatment of deep-seated tumors is 
a major challenge for traditional photodynamic therapy 
(PDT) due to difficulties in delivering light into the sub-
surface.  Lasers and light-emitting diodes (LEDs) are light 
sources that are commonly used in PDT, halogen and arc 
lamps can also be used in some cases. However, most 
photosensitizers (PSs), such as porphyrin derivatives, ab-
sorb in the ultraviolet or visible regions that overlap with 
the tissue absorption spectrum [109,110]. This makes it diffi-
cult to apply PDT in the clinic due to the short penetration 
depth of illumination light, which leads to ineffective 
treatment of tumors located deep under the skin. A poten-
tial solution to the limitation of PDT for deep tumor treat-
ment is developing near-infrared (NIR) photosensitizers. 
Due to the weak scattering and absorption of most tissue 
chromophores, including oxyhemoglobin, deoxyhemoglo-
bin, melanin, and fat in the NIR window, only light in the 
range of 700−1100 nm can penetrate deep into the tissue 
[111]. However, for practical applications, NIR light can 
still only penetrate 5 mm into the tissue because enough 
energy needs to be reserved for PS activation [112]. More-
over, reduced 1O2 generation efficiency has been reported 
by using NIR-activated PSs due to the narrow energy gaps 
and the faster non-radiative transition rate (when com-
pared with that of wide-band photosensitizers) [113,114].  
Another methodology used to achieve deeper tissue 
penetration is through utilizing an NIR laser as the light 
source. Even with this advancement, there is still room for 
further improvement of the penetration depth and the gen-
eration efficacy of 1O2 
[115]. To work on overcoming these 
problems, researchers introduced X-rays as an energy 
source to initiate PDT [116]. The utilization of X-rays as a 
PDT light source makes it feasible to integrate diagnosis, 
radiotherapy, and PDT for the next generation of tumor 
theranostic applications. In order to use X-rays in this 
technology, scintillator materials are used to convert the 
X-rays to UV/visible light since there is no PS that can 
directly absorb X-ray energy [117]. The scintillation process 
can be divided into three parts: (1) conversion of incom-
ing radiation into a large number of electron-hole pairs, 
(2) transfer of the electron-hole pairs’ energy to the lu-
minescent ions, and (3) emission of the luminescent ions 
that radiatively return from an excited state to the ground 
state [117,118]. Low energy beams (40-100 kV or “superficial” 
X-rays) are useful only for skin cancers because the beams 
can only penetrate <5 mm deep. Subsurface tumors re-
quire medium energies (200 kV to 1 MV orthovoltage and 
supervoltage Xrays). Presently, high-energy beams (4−25 
megavoltage [MV] or “deep” X-rays) are commonly used 
to treat deep tumors (>2 cm deep). The derived unit for 
absorbed dose is the gray (Gy), according to International 
System of Units, and is equivalent to 1 J of energy depos-
ited by ionizing radiation per kilogram of matter (1 Gy 
= 1 J/kg = 1 m2/s2) [119]. The Figure 2 shows principle of 
X-ray-activatable nanoparticles for PDT. The PS’s elec-
trons from the ground state (S0) will absorb energy and 
move to singlet-excited states (S1). Some of the absorbed 
energy will be released via intersystem crossing, and the 
promoted electron will move to a triplet excited state (T1). 
This triplet state has a relatively long half-life, allowing 
energy to be transferred to nearby oxygen molecules. This 
generates 1O2 in most cases via the type II pathway, which 
can damage the cells in the surrounding area.
Figure 2. Principle of X-ray-Activatable Nanoparticles for 
PDT. (A) Scintillating nanoparticles act as an X-ray trans-
ducer to generate 1O2 through the energy transfer process.  
(B) diagram of the PDT mechanism that occurs when ener-
gy is transferred from ScNPs to activate the PS [120]
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5. Nanotechnology in PDT
Despite the widespread and rapidly growing applica-
tions, PDT has yet to gain clinical acceptance as a first-
line oncological intervention due to certain limitations 
including lack of an ideal PS, challenges in formulating 
PS, choosing the right light dosimetry for a complete and 
effective treatment, difficulties in planning the treatment 
and monitoring the treatment response. The application 
of nanoparticles in PDT has been a major stride forward 
in resolving some of the challenges associated with clas-
sic PS. With the rapid development of nanoscience and 
technology in the past decade, phototherapies based on 
nanomaterials and nanotechnologies have attracted tre-
mendously increasing interest [121]. Over the past decade, 
nanoparticle-based PDT has emerged as an alternative to 
conventional PDT to effectively target cancer. PS-carry-
ing nanoparticles could increase the water solubility of 
PS molecules, enhance their tumor accumulation, and 
thus improve the therapeutic efficacy and specificity of 
PDT. In addition, nanotechnology provides a platform 
for the integration of multiple functionalities in a single 
construct. Various nanomaterials such as liposomes [122]. 
polymeric nanoparticles [123], magnetic nanoparticles [124-
126], quantum dots [127], carbon-based nanomaterials [128], 
mesoporous silica nanoparticles [129] as well as a number 
of other functional nanoparticles with interesting chemical 
and physical properties [130] have been developed for the 
delivery of PDT, showing encouraging results via and in 
vivo. The potential advantage of NPs is that a high ‘‘pay-
load’’ can be delivered and they can be ‘‘decorated’’ with 
multiple targeting moieties such as antibodies or peptides. 
Other approaches [131] include biodegradable polymers 
and ceramic (silica) and metallic (gold, iron oxide) NPs; 
magnetic NPs, in which an applied magnetic field enhanc-
es localization to the tumor; and hybrid NPs that allow 
both PDT and either another therapeutic strategy such 
as hyperthermia or an imaging technique such as MRI. 
NP delivery of 2-photon PSs has also been reported, be-
cause these typically have very poor water solubility [132]. 
Moreover, in recent years, another unique class of optical 
nanomaterials, Upconverting NPs have been investigat-
ed, in which relatively long wavelength light (NIR) is 
absorbed and converted to shorter wavelength light that 
activates the attached PS [133]. “Upconversion Nanopar-
ticles” (UCNs), a multifaceted tool that due to its recent 
accelerated progress shows great potential in augmenting 
the scope of PDT in the treatment of solid tumors. These 
concepts illustrate a general advantage of NP based PDT 
in that the photophysical and photochemical properties of 
the PS can be uncoupled from the delivery and activation 
processes. A final recent approach is the encapsulation of a 
PS inside polymeric NPs that in turn are incorporated into 
liposomes containing a second drug such as an antiangio-
genic agent (or vice versa) [134]. This co-delivery increases 
the therapeutic synergy of the 2 modalities. 
6. Combinations of PDT with Other Thera-
pies
Combinations of various therapeutic modalities with non-
overlapping toxicities are among the commonly used strat-
egies to improve the therapeutic index of treatments in 
modern oncology. Two general approaches may increase 
the antitumor effectiveness of PDT: (1) sensitization of 
tumor cells to PDT and (2) interference with cytoprotec-
tive molecular responses triggered by PDT in surviving 
tumor or stromal cells. Any interactions between PDT and 
PDT-sensitizing agents will be confined to the illuminated 
area. Therefore, the potentiated toxicity of the combina-
tions is not systemic. This should be of special importance 
in elderly or debilitated patients who tolerate more inten-
sive therapeutic regimes poorly. Moreover, considering 
its unique 1O2-dependent cytotoxic effects, PDT can be 
safely combined with other antitumor treatments without 
the risk of inducing cross-resistance [135]. There have been 
few studies on combinations of PDT with standard anti-
tumor regimens published to date [136]. PDT can be used 
in combination with surgery as a neoadjuvant, adjuvant, 
or repetitive adjuvant treatment, preferably fluorescence 
image guided to confine illumination to the most suspi-
cious lesions. PDT has also been successfully combined 
with radiotherapy (RT) and chemotherapy [137-139].  The 
promising emerging approach of using nanoparticles to 
enable the combination of PDT with RT for deep can-
cer treatment was proposed by Chen and Zhang in 2006 
[140]. Under this concept, luminescent nanoparticles were 
utilized for the delivery of PS such as porphyrin. Upon 
simulation by X-rays, the nanoparticles emit scintillation 
or persistent luminescence to activate the PS to generate 
singlet oxygen. The novel strategy described in this study 
involves the use of in vivo luminescent nanoparticles so 
that an external light source is not necessary to activate 
the photosensitizing agent within tumors. Moreover, Fig-
ure 3 shows high energy beams such as X-rays can pene-
trate deep tissue easily; therefore, after the PDT activation 
by X-ray, it will be feasible for deep cancer treatment [141]. 
The development of novel target-specific antitumor 
drugs has enabled examination of a number of con-
cept-based combinations that in various molecular mecha-
nisms sensitize tumor cells to the cytotoxic effects of PDT. 
Proteins are major targets for oxidative reactions because 
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they constitute nearly 70% of the dry weight of cells. Ox-
idized proteins can be refolded by molecular chaperones 
such as HSPs. Inefficient restoration of their structure 
leads to accumulation of misfolded proteins and their 
aggregation, which precipitates cell death. Accumulation 
of damaged or misfolded proteins within ER triggers a 
process called ER stress, which can be ameliorated by un-
folded protein response or can lead to cell death [142]. Ther-
apeutic approaches that interfere with refolding or remov-
al of oxidized proteins can be used to sensitize tumor cells 
to PDT. For example, modulation of HSP function with 
geldanamycin, a HSP90 inhibitor, sensitizes tumor cells to 
PDT [143]. Bortezomib, a proteasome inhibitor successfully 
used in the treatment of haematological disorders, poten-
tiates the cytotoxic effects of PDT by aggravation of ER 
stress [144]. Moreover, several apoptosis-modulating factors 
such as rapamycin, Bcl-2 antagonists, ursodeoxycholic 
acid, or ceramide analogues have been shown to increase 
PDT-mediated cancer cell death. Transformed cells deep-
ly seated within the tumor mass receive suboptimal light 
doses and survive due to induction of numerous cytopro-
tective mechanisms. Targeting enzymes participating in 
ROS scavenging (such as superoxide dismutase, HO-1, or 
nitric oxide synthase) with selective inhibitors has been 
shown to improve the antitumor activity of PDT [145,146,147]. 
Antivascular effects of PDT can be further potentiated by 
cyclooxygenase (COX) inhibitors, [148] antiangiogenic or 
antivascular drugs, [149] or monoclonal antibodies targeting 
factors promoting neovascularization (such as vascular 
endothelial growth factor), [150] significantly improving 
tumor growth control after PDT. Finally, combining PDT 
with agents that target signal transduction pathways such 
as the anti-epidermal growth factor receptor agent cetux-
imab may also improve the efficacy of PDT. [151] More-
over, combining 2 different PSs in one treatment regimen 
leads to simultaneous targeting of tumor as well as vascu-
lar cells [152]. The use of agents that enhance the efficacy 
without increasing the normal tissue effects of PDT, there-
by improving the therapeutic index, will represent a major 
focus of clinical research going forward.
7. Current Limitations of PDT
In spite of solving so many problems and resolving re-
strictions regarding PDT, there are still limitations of 
PDT treatment. Although it delivers site-specific therapy, 
its acceptance in clinical practice as a mainstream can-
cer treatment modality is hindered, for the most part, by 
accumulation of sensitisers in skin.  As discussed in the 
previous sections, PDT proves to be effective in inducing 
tumor responses as well as improving patient survival 
and quality of life. Efficacy is seen when PDT is part of a 
multimodal approach, is used as a first-line treatment for 
premalignant or early disease and as standalone palliative 
treatment. Even though PDT shows great potential, there 
are still some limitations that prevent a firm position for 
PDT in standard care regimen of cancer. When review-
ing the clinical trials and studies done over the last few 
years, some general problems become evident. A major 
problem is related to the adverse events (AEs) associated 
with PDT. With systemically administered PSs, especial-
ly of the first generation, skin photosensitivity is one of 
the most common AEs. Patients have to avoid sunlight 
and strong artificial light for weeks, which is highly un-
desirable when they are nearing the end of life. Another 
AE often reported is pain. The main mechanism in PDT 
induced pain has yet to be elucidated, but several studies 
have found some predictors of pain. The biggest predic-
tors appear to be the size of the treated area while loca-
tion, PS type, lesion type, gender, age and light protocol 
have also been mentioned [153]. Several strategies of pain 
management have been tested but none fully relieved PDT 
induced pain [153]. The occurrence of AEs like inflamma-
tion, fever and nausea are typically location dependent 
but are often successfully managed with medication. 
Another drawback is the decreasing efficacy of PDT for 
larger lesions, especially with first generation PSs. Due to 
inadequate tissue penetration of light or PS, bulky or deep 
seated tumors are difficult to treat with PDT. Especially 
Figure 3. Schematic of combination therapy of radiother-
apy and photodynamic therapy. Ionizing radiation is used 
to excite scintillating nanoparticles, which may be located 
deep within tissue. The nanoparticles transfer energy to 
the attached photosensitizer molecules, killing cells by the 
same mechanism as photodynamic therapy [141]
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evident with Photofrin® and 5-ALA, the limited penetra-
tion of the appropriate light prevents sufficient depth of 
tumoricidal action [154]. Even second generation PSs per-
form less in larger lesions in which case surgery is more 
effective [155,156]. The most effective PSs tend to be hard to 
dissolve due to hydrophobicity and can form aggregates 
that have trouble penetrating tumor tissue [157]. Besides 
larger lesions, PDT is also not indicated for metastasizing 
tumors. Almost all clinical studies exclude patients with 
tumor metastasis as it is almost impossible to reach those 
tumors with light. Metastasis remains one of the largest 
challenges in cancer therapy and PDT is no exception. 
Tumor recurrence is often reported in clinical trials, prob-
ably due to inadequate tumor eradication. Not only insuf-
ficient penetration, but also the presence of PDT resistant 
tumor tissues due to hypoxia probably adds to the chance 
of recurrence. Although the reason for recurrence often 
lies beyond the scope of clinical trials, the importance of 
pre-existing hypoxia in cancer therapy outcome is well 
known [158,159]. It is believed, however, that with improved 
technology, dosimetry and new PSs the above limitations 
could be overcome in the future.
8. PDT in the Future
Researchers continue to study ways to improve the effec-
tiveness of PDT and expand it to other cancers. Clinical 
trials (research studies) are under way to improve/evaluate 
the use of PDT for cancers of the brain, skin, prostate, cer-
vix, and peritoneal cavity (the space in the abdomen that 
contains the intestines, stomach, and liver). Other research 
is focused on the development of photosensitizers that 
are more powerful, more specifically target cancer cells 
[160] and are activated by light that can penetrate tissue and 
treat deep or large tumors. Recently the addition of other 
photo-activated therapeutics that improves the anti-tumor 
potential of PS based theranostics has often been investi-
gated. The use of light activated photothermal therapeutic 
(PTT) agents can increase the overall cell killing effect 
compared to PDT alone, while the nanocarrier also hol-
sters efficient imaging modalities for image-guided PTT/
PDT [161,162]. These multifunctional nanoplatforms can be-
come even more complex by incorporation of chemother-
apeutics [163,164]. The interest in combining diagnostics and 
therapeutics in the field of PDT is illustrated by the vast 
body of literature from the last couple of years, describing 
the ideas and endless possibilities to create multi-layered 
PDT-based theranostics. These multifunctional modali-
ties will improve the applicability of PDT and possibly 
strengthen its position in the clinic. Not only will nanoma-
terials provide a scaffold for both PS and targeting moi-
eties, they will also enable the incorporation of imaging 
agents and other therapeutics to improve PDT efficacy 
and applicability [165]. Nevertheless, with the monoclonal 
antibodies conjugated PSs, the increased size of such 
complex theranostic platforms might negatively affect PS 
circulation times and tissue penetration. Further studies 
are needed to show the applicability of such compounds. 
One of the hallmarks of PDT is the inflammatory re-
sponse following treatment-induced tumor cell death. This 
response is also crucial for the development of anti-tumor 
immunity [166]. Few pre-clinical studies have shown the 
occurrence of tumor immunogenicity, control of distant 
disease and protection for further tumor challenges [167]. 
Considerable effort is put into understanding the mecha-
nisms underlying tumor immune response and systemic 
anti-tumor immunity and exploring how to exploit them 
to improve PDT efficacy [168]. Earlier work mentions sev-
eral ways of stimulating the immune system to improve 
anti-tumor immune-reactions after PDT. Administration 
of inflammatory cytokines such as tumor necrosis factor 
(TNF)-α or macrophage colony stimulating factor or the 
local administration of pathogen-associated molecular 
patterns (PAMPs) such as bacterial or fungal components 
stimulated the immune-system and improved PDT effi-
cacy [169,170]. The application of PAMPs to improve PDT 
induced tumor immunity is still being investigated. Peri-
tumoral injection of CpG oligodeoxynucleotides, a TLR-9 
agonist used in clinical trials to improve immunotherapy, 
resulted in tumor directed migration of primed DCs that 
show enhanced phagocytosis, maturation and antigen 
presentation to T-cells. When combined with PDT, this 
ultimately results in prolonged host survival in a meta-
static murine breast cancer model compared to PDT alone 
[171]. Modulating gene expression by epigenetic reversal 
can also aid in enhancing PDT anti-tumor effect. Essen-
tial components in eliciting an immune response such 
as MHC I or tumor associated antigens (TAA) are often 
downregulated in cancers [172]. The importance of TAA in 
anti-tumor responses was elucidated when PDT treatment 
of P1A positive tumors elicited an epitope-specific im-
mune response while treatment of P1A negative tumors 
did not [173]. Additionally, PDT is used to generate thera-
peutic or prophylactic anti-tumor vaccines based on tu-
mor cells or lysates obtained after ex vivo PDT [174]. PDT 
generated cell lysates proved more effective than lysates 
generated by UV or ionizing irradiation or freeze thaw 
cycles in inducing an immune response [175]. Following 
cell lysate vaccination, several studies reported stimulated 
DC migration and maturation, enhanced T-cell activation 
and tumor specific immune recognition leading to tumor 
growth inhibition, prolonged survival time and acquisition 
of resistance against rechallenge in mice [175,176]. Similar 
DOI: https://doi.org/10.30564/jim.v8i1.780
12
Journal of Integrative Medicine | Volume 08 | Issue 01 | June 2019
Distributed under creative commons license 4.0
results were seen after administration of PDT treated 
whole tumor cells as a cancer vaccine [177].
9. Conclusion
Photodynamic therapy (PDT) is an emerging cancer treat-
ment that takes advantage of the interaction between light 
and a photosensitizing agent to initiate apoptosis of cancer 
cells.  Photodynamic therapy (PDT) offers a minimally 
invasive, effective and highly controllable therapeutic 
strategy, and has become popular as an alternative or addi-
tional approach to conventional cancer treatments, such as 
chemotherapy and surgery. The increasing popularity of 
this treatment method is largely due to its selectivity: only 
tissues that are simultaneously exposed to the photosen-
sitizer and light, in the presence of oxygen, are the ones 
subjected to the cytotoxic reactions during PDT. Thus, 
under ideal circumstances only diseased tissues are erad-
icated, leaving the surrounding healthy cells undamaged. 
With several commercially available photosensitizing 
agents now on the market, numerous well designed clini-
cal trials have demonstrated the efficacy of PDT on vari-
ous cutaneous and deep tissue tumors. Moreover, PDT-in-
duced immunogenic cell death associated with induction 
of a potent local inflammatory reaction offers the possibil-
ity to flourish into a therapeutic procedure with excellent 
local antitumor activity and the capability of boosting the 
immune response for effective destruction of metastases. 
However, current photosensitizers and light sources still 
suffer a number of challenges. Future PDT will build on 
those findings to allow development and refinement of 
more optimal therapeutic agents and illumination devices. 
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